Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology
Disease Category: Parkinson's Disease
Trial Information
Phase II - Assessing the efficacy and safety of a new investigational drug when used together with a stable dose of L-dopa in the treatment of Parkinson's Disease
The purpose of the study is to assess the efficacy and safety of
a range of doses of a new investigational drug when used together
with a stable dose of L-dopa to treat Parkinson's Disease.
Patient Inclusion Criteria:
- Moderate to severe Parkinson's Disease for at least five
years, experiencing motor fluctuation and dyskinesias
- Age 30 and older
- Must have been on L-dopa for at least two years, dose must have
been stable for the past four months
- Hoehn and Yahr score: 2.5 - 4 in the "off"
states
Patient Exclusion Criteria:
- History or presence of major psychological disorders
- Unstable medical conditions
- Consumption of more than 8oz of alcohol per day
- Taking the drugs tolcapone or hepatotoxic drugs
Sanja Obradov, Research Coordinator
Banner Sun Health Research Institute
10515 W. Santa Fe Drive
Sun City, AZ 85351
Phone: 623-876-5468
View Google Map
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
